慢性阻塞性肺疾病急性发作期患者血浆纤溶酶原激活物及其抑制物活性研究  

作　　者：辛萍[1] 庞宝森[1] 张海燕[1] 黄秀霞[1] 郭素良[1] 

机构地区：[1]首都医科大学附属北京朝阳医院北京呼吸疾病研究所呼吸基础实验室,100020

出　　处：《中国医药》2012年第2期140-141,共2页China Medicine

摘　　要：目的探讨慢性阻塞性肺疾病急性发作期（AECOPD）患者血浆纤溶酶原激活物（t-PA）及纤溶酶原激活物抑制物（PAI一1）测定的意义。方法选取2007年3月至2010年9月因AECOPD入院的患者203例作为AECOPD组；选取同期进行健康体检的健康人群142例作为正常对照组。应用酶联免疫吸附法检测2组t-PA及PAI一1含量。结果AECOPD组血浆t-PA含量为（4．4±4．1）“g／L，正常对照组为（7．3±1．4）¨g／L，2组比较差异有统计学意义（P〈0．01）；AECOPD组血浆PAI一1含量为（42±14）卜∥L，正常对照组为（19±9）¨g／L，2组比较差异有统计学意义（P〈0．01）。结论AECOPD患者存在高凝状态，易导致肺细小动脉血栓形成。血浆t-PA及PAI一1含量测定对早期发现AECOPD患者是否存在高凝状态有一定的临床意义。Objective To explore clinical significances of plasma tissue-type plasminogen activator(t-PA) and type 1 plasminogen activator inhibitor ( PAI-1 ) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods Two hundred and three patients hospitalized with AECOPD from 2007 to 2010 were chosen as the AECOPD group,while 142 normal persons receiving general health check-up during the same period were arranged for normal control group.Results The value of plasma t-PA in AECOPD patients was significantly lower than that in the normal control group [ (4.4 ± 4.1 ) μg/L vs (7.3 ± 1.4) μg/L,P ＜ 0.01 ] ; and the value of plasma PAI-1 in AECOPD patients was significantly higher than that in the normal control group[ (42 ± 14) μg/L vs ( 19 ±9) μg/L,P ＜ 0.01 ].Conclusions The blood of patients with AECOPD is in a hypercoagulation state,which can easily result in thrombosis of small pulmonary arteries and arterioles.The detection of plasma t-PA and PAI-1 has a certain clinical significance in discovering if there is a hypercoagulation state in AECOPD patients in the early stage.

关 键 词：血浆纤溶酶原激活物 慢性阻塞性肺疾病 COPD患者 急性发作期 抑制物活性 AECOPD 纤溶酶原激活物抑制物 血浆T-PA 

分 类 号：R563[医药卫生—呼吸系统]